Eton Pharmaceuticals (ETON) vs Vera Therapeutics (VERA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Eton Pharmaceuticals (ETON) has outperformed Vera Therapeutics (VERA) over the past year, gaining 269.7% versus a loss of 10.6%. Over five years, ETON leads with a +1341.9% price change compared with -15.2% for VERA. Vera Therapeutics is the larger company by market cap ($1.84 billion vs $1.76 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ETON | VERA |
|---|---|---|
| Share price | $60.85 | $25.45 |
| Market cap | $1.76B | $1.84B |
| 1-day change | -0.83% | -4.86% |
| YTD return | +259.85% | -49.74% |
| 1-year return | +269.68% | -10.58% |
| 5-year return | +1341.94% | -15.17% |
| P/E ratio (TTM) | 39.51 | — |
| Forward P/E | 18.41 | — |
| EPS (TTM) | $1.54 | $-5.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $79.95M | — |
| Revenue growth (YoY) | +104.94% | — |
| Net income (latest FY) | $-4.60M | $-299.62M |
| Gross margin | 53.46% | — |
| Operating margin | -1.06% | — |
| Net margin | -5.75% | — |
| 52-week high | $70.64 | $56.05 |
| 52-week low | $14.27 | $25.08 |
| Distance from 52-week high | -13.86% | -54.59% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +32.70% | +180.39% |
| Average volume | 570.79K | 1.95M |
| Shares outstanding | 28.84M | 72.30M |
| Employees | 44 | 362 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ETON has outperformed VERA by 280.3 percentage points over the past year.
About Eton Pharmaceuticals
ETON stock →Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees
About Vera Therapeutics
VERA stock →Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 362 employees
ETON vs VERA FAQ
Which is bigger, Eton Pharmaceuticals or Vera Therapeutics?
Vera Therapeutics (VERA) is larger, with a market capitalization of $1.84B compared with $1.76B for Eton Pharmaceuticals (ETON).
Which stock has performed better over the past year, ETON or VERA?
ETON returned +269.68% over the past 12 months, compared with -10.58% for VERA (price return, excluding dividends). Past performance does not predict future results.
Are Eton Pharmaceuticals and Vera Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.